These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The American Urological Association symptom score in the evaluation of men with lower urinary tract symptoms: at 2 years of followup, does it work? Kaplan SA; Olsson CA; Te AE J Urol; 1996 Jun; 155(6):1971-4. PubMed ID: 8618299 [TBL] [Abstract][Full Text] [Related]
3. Finasteride in benign prostatic hyperplasia. Verhamme KM; Bosch RJ; Sturkenboom MC N Engl J Med; 2004 Mar; 350(13):1359-61; author reply 1359-61. PubMed ID: 15049034 [No Abstract] [Full Text] [Related]
4. What's best for your patient with BPH? Neal RH; Keister D J Fam Pract; 2009 May; 58(5):241-7. PubMed ID: 19442387 [TBL] [Abstract][Full Text] [Related]
5. Benign prostatic hyperplasia: use of drug therapy in primary care. Beduschi R; Beduschi MC; Oesterling JE Geriatrics; 1998 Mar; 53(3):24-8, 33-4, 37-40. PubMed ID: 9511773 [TBL] [Abstract][Full Text] [Related]
6. [Benign hypertrophy of the prostate: which treatment, for whom?]. Schulman C Rev Med Brux; 1999 Sep; 20(4):A212-8. PubMed ID: 10523895 [TBL] [Abstract][Full Text] [Related]
7. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery. Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985 [TBL] [Abstract][Full Text] [Related]
8. [Medical therapy of benign prostatic hyperplasia]. Altarac S Lijec Vjesn; 2005; 127(11-12):316-23. PubMed ID: 16583940 [TBL] [Abstract][Full Text] [Related]
9. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Miner M; Rosenberg MT; Perelman MA Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576 [TBL] [Abstract][Full Text] [Related]
10. The role of combination medical therapy in benign prostatic hyperplasia. Greco KA; McVary KT Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123 [TBL] [Abstract][Full Text] [Related]
11. Diagnosis and management of benign prostatic hyperplasia. Edwards JL Am Fam Physician; 2008 May; 77(10):1403-10. PubMed ID: 18533373 [TBL] [Abstract][Full Text] [Related]
15. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992-2002). Vela-Navarrete R; Gonzalez-Enguita C; Garcia-Cardoso JV; Manzarbeitia F; Sarasa-Corral JL; Granizo JJ BJU Int; 2005 Nov; 96(7):1045-8. PubMed ID: 16225526 [TBL] [Abstract][Full Text] [Related]
16. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. Roehrborn CG BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681 [TBL] [Abstract][Full Text] [Related]
17. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications. Seftel A; Rosen R; Kuritzky L Int J Impot Res; 2007; 19(4):386-92. PubMed ID: 17377613 [TBL] [Abstract][Full Text] [Related]
19. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia. Marberger M Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191 [TBL] [Abstract][Full Text] [Related]
20. The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia. Agha AH; Roy JB; Culkin DJ; Lyon K Adv Ther; 1995; 12(6):361-6. PubMed ID: 10163332 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]